A phase II clinical study (NCT04150575) investigated HLX10 (a new anti-PD-1 antibody) combined with albumin and paclitaxel as second-line therapy for advanced cervical cancer or patients with advanced cervical cancer who could not tolerate toxicity (54). Here, ALB is linked to cervical cancer.